SVRA Stock Summary and Trading Ideas (Savara | NASDAQ:SVRA)

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Savara trades on the NASDAQ stock market under the symbol SVRA.

As of May 6, 2024, SVRA stock price climbed to $4.90 with 516,497 million shares trading.

SVRA has a beta of 1.23, meaning it tends to be more sensitive to market movements. SVRA has a correlation of 0.08 to the broad based SPY ETF.

SVRA has a market cap of $676.93 million. This is considered a Small Cap stock.

In the last 3 years, SVRA stock traded as high as $5.70 and as low as $1.02.

The top ETF exchange traded funds that SVRA belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

SVRA has outperformed the market in the last year with a return of +159.3%, while the SPY ETF gained +27.9%. However, in the most recent history, SVRA shares have underperformed the stock market with its stock returning +1.0% in the last 3 month period and +1.9% for the last 2 week period, while SPY has returned +4.5% and +4.0%, respectively.

SVRA support price is $4.48 and resistance is $4.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SVRA stock will trade within this expected range on the day.